Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease

Last updated: September 27, 2013
Sponsor: Chulalongkorn University
Overall Status: Completed

Phase

4

Condition

Neurologic Disorders

Tardive Dyskinesia

Dyskinesias

Treatment

N/A

Clinical Study ID

NCT01662414
53653
  • Ages 30-80
  • All Genders

Study Summary

This is a double-blind, placebo-controlled, Phase IV trial , comparing HMS 90® versus placebo (soy protein) as add-on (adjuvant) therapy in subjects with idiopathic Parkinson's Disease.

The principal objective is to evaluate the changes in biomarkers of oxidative stress and,plasma amino acids, as well as improvement of clinical symptoms and brain function

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Subjects with Idiopathic Parkinson's Disease

  2. Subjects who are willing and able to participate in the trial and has providedwritten, informed consent.

Exclusion

Exclusion Criteria:

  1. Subjects who are allergic to Whey protein (HMS 90®).

  2. Subjects who are treated with chemotherapy .

  3. Subjects with any history of neurodegenerative diseases, e.g., Alzheimer's disease.

  4. Subjects with history of diabetes. 4.5. Subjects with abnormal liver function test

Study Design

Total Participants: 38
Study Start date:
April 01, 2011
Estimated Completion Date:
December 31, 2012

Connect with a study center

  • Chulalongkorn University Hospital

    Pathumwan, Bangkok 10330
    Thailand

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.